Abstract
BackgroundStudies showed that the endotoxemia-related biomarker, lipopolysaccharide-binding protein (LBP), is associated with obesity and fatty liver. The level of LBP is reduced after surgical weight loss. This study aimed to verify the change of serum LBP levels after one-year medical weight management in subjects with obesity.Methods and findingsA total of 62 subjects with obesity, 39 subjects with overweight, and 21 subjects with normal body mass index were enrolled for a one-year weight management program. Basic information, body composition analysis, clinical data, serum LBP level, and abdominal ultrasonography findings were collected. At baseline, the serum LBP levels of the obese and overweight subjects were significantly higher than that of the normal group (30.9±7.4 and 29.6±6.3 versus 23.1±5.6 μg/mL, respectively, p<0.001). Serum LBP in subjects with obesity was significantly reduced to 26.5±7.1 μg/mL (p-value < 0.001) after one year. In the multivariate analyses, LBP was associated with high sensitive C-reactive protein (hs-CRP) and non-alcoholic fatty liver disease (NAFLD) fibrosis score (NFS) before weight management in the obese group. Moreover, the change of LBP in response to weight management was significantly related to the changes of hs-CRP, leukocyte count and NFS by multivariate linear regression analysis also in the obese group.ConclusionThe serum level of the endotoxemia-related biomarker, LBP, decreases after one-year weight management in the obese subjects. In addition to serving as a metainflammatroy biomarker like hs-CRP, LBP may also be a potential biomarker as a non-invasive biomarker for the evaluation of liver fibrosis in NAFLD.
Highlights
The prevalence of obesity increased significantly worldwide over the past few decades [1]
lipopolysaccharide-binding protein (LBP) was associated with high sensitive C-reactive protein and nonalcoholic fatty liver disease (NAFLD) fibrosis score (NFS) before weight management in the obese group
In addition to serving as a metainflammatroy biomarker like high sensitive C-reactive protein (hs-CRP), LBP may be a potential biomarker as a non-invasive biomarker for the evaluation of liver fibrosis in non-alcoholic fatty liver disease (NAFLD)
Summary
The prevalence of obesity increased significantly worldwide over the past few decades [1]. People with obesity have an increased risk of comorbidities, such as non-alcoholic fatty liver disease (NAFLD), cancer, cardiovascular disease, type 2 diabetes mellitus (T2DM), hypertension, osteoarthritis, and stroke [2]. NAFLD is a disease involving hepatic fat accumulation and inflammation with the potential to progress from simple steatosis to non-alcoholic steatohepatitis (NASH), cirrhosis, and even to liver cancer [4]. Since current evidence does not support routine use of a liver biopsy in patients with suspected NAFLD or NASH [4], non-invasive tests such as liver enzyme levels, medical images, Fatty Liver Index, NAFLD fibrosis score (NFS), fibrosis-4 (FIB-4), and ultrasound methods are widely used as surrogate indicators [4, 6]. Studies showed that the endotoxemia-related biomarker, lipopolysaccharide-binding protein (LBP), is associated with obesity and fatty liver. This study aimed to verify the change of serum LBP levels after one-year medical weight management in subjects with obesity
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
